PMID- 29863106
OWN - NLM
STAT- MEDLINE
DCOM- 20181016
LR  - 20181202
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 24
DP  - 2018 Jun 4
TI  - Synergistic Effect of Atorvastatin and Folic Acid on Cardiac Function and 
      Ventricular Remodeling in Chronic Heart Failure Patients with 
      Hyperhomocysteinemia.
PG  - 3744-3751
LID - 10.12659/MSM.906893 [doi]
AB  - BACKGROUND At present, a constant progress in pathophysiology understanding and 
      treatment of the chronic heart failure (CHF) is arising. Meanwhile, 
      hyperhomocysteinemia (HHcy) has been linked to impaired left ventricular function 
      and clinical class in patients with CHF. Atorvastatin therapy can reduce the 
      incidence of sudden cardiac death in patients with advanced CHF. Folic acid could 
      enhance endothelial function in vascular disease states. The present study aims 
      to investigate the effect of atorvastatin and folic acid combined on the cardiac 
      function and ventricular remodeling in CHF patients with HHcy. MATERIAL AND 
      METHODS Elderly CHF patients with HHcy were divided into four groups: routine, 
      routine + atorvastatin, routine + folic acid, and routine + atorvastatin + folic 
      acid groups. Serum homocysteine (Hcy) level was detected using enzymatic cycling 
      methods, and N-terminal pro brain natriuretic peptide (NT-proBNP) level by ELISA. 
      The cardiac function indexes and left ventricular early diastolic peak flow 
      velocity/atrial systolic peak flow velocity (E/A) ratio were evaluated. The 
      six-minute walk test was performed to measure the six-minute walk distance 
      (6MWD). RESULTS 6MWD increased, the serum Hcy and NT-proBNP levels decreased, and 
      cardiac function was improved compared with before treatment, which was the most 
      significant in the routine + atorvastatin + folic acid group, followed by the 
      routine + atorvastatin group, then the routine + folic acid group, and lastly, 
      the routine group. CONCLUSIONS The results indicated that the combination of 
      atorvastatin and folic acid improved the cardiac function and inhibited 
      ventricular remodeling of elderly CHF patients with HHcy.
FAU - Peng, You
AU  - Peng Y
AD  - Department of Geriatric, Hunan Provincial People's Hospital, The First Affiliated 
      Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
FAU - Ou, Bai-Qing
AU  - Ou BQ
AD  - Department of Geriatric, Hunan Provincial People's Hospital, The First Affiliated 
      Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
FAU - Li, Hua-Hua
AU  - Li HH
AD  - Department of Geriatric, Hunan Provincial People's Hospital, The First Affiliated 
      Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
FAU - Zhou, Zhi
AU  - Zhou Z
AD  - Department of Cardiology, Hunan Provincial People's Hospital, The First 
      Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China 
      (mainland).
FAU - Mo, Jiong-Ling
AU  - Mo JL
AD  - Department of Geriatric, Hunan Provincial People's Hospital, The First Affiliated 
      Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
FAU - Huang, Jue
AU  - Huang J
AD  - Department of Cardiology, Hunan Provincial People's Hospital, The First 
      Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China 
      (mainland).
FAU - Liang, Feng-Ling
AU  - Liang FL
AD  - Department of Cardiology, Hunan Provincial People's Hospital, The First 
      Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China 
      (mainland).
LA  - eng
PT  - Journal Article
DEP - 20180604
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 935E97BOY8 (Folic Acid)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Atorvastatin/metabolism/pharmacology/*therapeutic use
MH  - China
MH  - Chronic Disease
MH  - Female
MH  - Folic Acid/metabolism/pharmacology/*therapeutic use
MH  - Heart Failure/drug therapy/physiopathology
MH  - Heart Function Tests/drug effects
MH  - Humans
MH  - Hyperhomocysteinemia/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Ventricular Remodeling/drug effects
PMC - PMC6015480
COIS- Conflicts of interests None.
EDAT- 2018/06/05 06:00
MHDA- 2018/10/17 06:00
PMCR- 2018/06/04
CRDT- 2018/06/05 06:00
PHST- 2018/06/05 06:00 [entrez]
PHST- 2018/06/05 06:00 [pubmed]
PHST- 2018/10/17 06:00 [medline]
PHST- 2018/06/04 00:00 [pmc-release]
AID - 906893 [pii]
AID - 10.12659/MSM.906893 [doi]
PST - epublish
SO  - Med Sci Monit. 2018 Jun 4;24:3744-3751. doi: 10.12659/MSM.906893.